HLN vs. SN, GSK, HIK, HCM, INDV, BMK, APH, BXP, AGY, and ANCR
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Smith & Nephew (SN), GSK (GSK), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Benchmark (BMK), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), and Animalcare Group (ANCR). These companies are all part of the "medical" sector.
Haleon (LON:HLN) and Smith & Nephew (LON:SN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
Haleon has higher revenue and earnings than Smith & Nephew. Haleon is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Haleon has a net margin of 9.64% compared to Smith & Nephew's net margin of 4.74%. Haleon's return on equity of 6.70% beat Smith & Nephew's return on equity.
Smith & Nephew received 548 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 62.00% of users gave Smith & Nephew an outperform vote while only 27.78% of users gave Haleon an outperform vote.
In the previous week, Haleon had 3 more articles in the media than Smith & Nephew. MarketBeat recorded 3 mentions for Haleon and 0 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 0.00 beat Haleon's score of -0.20 indicating that Smith & Nephew is being referred to more favorably in the news media.
33.6% of Haleon shares are held by institutional investors. Comparatively, 55.7% of Smith & Nephew shares are held by institutional investors. 22.6% of Haleon shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Haleon presently has a consensus price target of GBX 356, indicating a potential upside of 8.21%. Smith & Nephew has a consensus price target of GBX 1,346.20, indicating a potential upside of 31.53%. Given Smith & Nephew's stronger consensus rating and higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Haleon.
Haleon pays an annual dividend of GBX 6 per share and has a dividend yield of 1.8%. Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 2.9%. Haleon pays out 5,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Smith & Nephew beats Haleon on 10 of the 19 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
